Wire Stories

Category Added in a WPeMatico Campaign

01_CANbridge_Logo_1

Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database